1. Medtech Insight
  2. >>Business

Capstan Medical Raises $31.4M Series B To Progress Heart Valve Tech Into Human Trials

 
• By Marion Webb

The heart tech company plans to use the new funding to test its robotics- and catheter-based solution for treating mitral and tricuspid valve disease in humans.

Heart Valve
• Source: Shutterstock (Shutterstock)

Heart tech company Capstan Medical announced on 9 August it raised $31.4m in a series B round of funding, led by venture capital firm Eclipse with participating investors including Intuitive Ventures and Puma Venture Capital.

The Santa Cruz, CA-based company plans to use the newly raised monies to expand its engineering, clinical development and operations...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 
• By Brian Bossetta

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By Marion Webb

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By Shubham Singh

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.